Clinical Trial Update: Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating trebananib with or without other targeted therapies for advanced renal cell carcinoma has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Cancer Ajcc V7
• Renal Cell Carcinoma
• Sarcomatoid Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Pazopanib (Pazopanib)
• Sorafenib (Sorafenib)
• Sunitinib (sunitinib)
• Trebananib (trebananib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-06-07